A Phase 4 interventional study of Timolol Maleate in Sorbate and Timolol hemihydrate in Glaucoma, Open Angle and Ocular Hypertension, sponsored by Vistakon Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2015-03-06.
Sponsored by Vistakon Pharmaceuticals · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing timolol in Glaucoma, Open-Angle — none open to participants now, none under way, none of them phase 3. Timolol · Glaucoma, Open-Angle.
Among the 24 studies testing timolol in Glaucoma, Open-Angle, this one is the 23rd largest by enrollment, is one of 2 that started in 2008, is one of 13 in phase 4, and was the 8th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →None of the 24 studies testing timolol in Glaucoma, Open-Angle is open now. The open studies under Glaucoma, Open-Angle, anywhere →
Timolol: first FDA approval 1978 (TIMOPTIC), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 5 · Phase 4 13
First in 1998; this study’s year is marked. 2 started in 2008.
This study's enrollment of 30 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 77 across the 24 interventional studies. Of the 22 that completed or were terminated, 8 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 24 have an industry lead sponsor. The 10 most frequent:
Vistakon Pharmaceuticals is the lead sponsor of 13 studies on the registry; none are open to participants now.
Vistakon Pharmaceuticals has 4 studies filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing timolol in Glaucoma, Open-Angle, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study compares patient symptoms and anterior segment safety in patients treated with timolol hemihydrate, generic timolol gel forming solution or timolol maleate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate 0.5% Period three - Timolol maleate gel forming solution 0.5%
Drug: Timolol Maleate in Sorbate · Drug: Timolol hemihydrate · Drug: Timolol maleate gel forming solution
Period one - Timolol maleate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol hemihydrate 0.5%
Drug: Timolol Maleate in Sorbate · Drug: Timolol hemihydrate · Drug: Timolol maleate gel forming solution
Period one - Timolol maleate gel forming solution 0.5% Period two - Timolol hemihydrate 0.5% Period three - Timolol maleate 0.5%
Drug: Timolol Maleate in Sorbate · Drug: Timolol hemihydrate · Drug: Timolol maleate gel forming solution
Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol maleate 0.5%
Drug: Timolol Maleate in Sorbate · Drug: Timolol hemihydrate · Drug: Timolol maleate gel forming solution
Period 1 - Timolol maleate 0.5% Period 2 - Timolol hemihydrate 0.5% Period 3 - Timolol maleate gel forming solution 0.5%
Drug: Timolol Maleate in Sorbate · Drug: Timolol hemihydrate · Drug: Timolol maleate gel forming solution
Period 1 - Timolol maleate gel forming solution 0.5% Period 2 - Timolol maleate 0.5% Period 3 - Timolol hemihydrate 0.5%
Drug: Timolol Maleate in Sorbate · Drug: Timolol hemihydrate · Drug: Timolol maleate gel forming solution
0.5%
0.5%
0.5%
Stinging on Instillation
Assessed from subject response to survey question asking about tolerability of medicine upon instillation, using a 0 through 7 scale, with 0=complete comfort and 7=worst pain imaginable.
Time frame: following 3 days of treatment
Conjunctival Hyperemia
Assessed by investigator using a slit lamp and a photographic grading scale. Photographs were graded: grade 0, grade 1, grade 2, grade 3. The higher the graded the worse the hyperemia.
Time frame: following 3 days of treatment
Tear Film Break-up Time
Time frame: following 3 days of treatment
Corneal Staining Grade
Assessed by the investigator using a slit lamp and Oxford Scheme, grading 0,1,2,3,4,5. The higher the grade the worse the staining.
Time frame: following 3 days of treatment
Corneal Staining Count
Assessed by the investigator using a slit lamp, counting the number of spots.
Time frame: following 3 days of treatment
Intraoclular Pressure
Time frame: following 3 days of treatment
Basic Schirmer's
Schirmer's measures basic tear function. The higher the number, the less dry the eye.
Time frame: following 3 days of treatment
Conjunctival Staining - Nasal Grade
Assessed by investigator using a slit lamp and the Oxford Scheme, grading 0,1,2,3,4,5 according to pictures provided. The higher the grade the worse the staining.
Time frame: following 3 days of treatment
Conjunctival Staining - Nasal Count
Assessed by investigator using slit lamp and counting number of spots.
Time frame: following 3 days of treatment
Conjunctival Staining - Temporal Grade
Assessed by investigator using a slit lamp and Oxford Scheme, grading 0,1,2,3,4,5 according to pictures provided. The higher the grade the worse the staining.
Time frame: following 3 days of treatment
Conjunctival Staining - Temporal Count
Assessed by investigator using a slit lamp and counting number of spots.
Time frame: following 3 days of treatment
Visual Acuity
The visual acuity score is a count of the number of letters the subject successfully read from the eye chart. The higher the score, the better the vision.
Time frame: following 3 days of treatment
| Milestone | Hemihydrate/Maleate/Maleate Gel | Maleate/Maleate Gel/Hemihydrate | Maleate Gel/Hemihydrate/Maleate | Hemihydrate/Maleate Gel/Maleate | Maleate/Hemihydrate/Maleate Gel | Maleate Gel/Maleate/Hemihydrate |
|---|---|---|---|---|---|---|
| Started | 3 | 5 | 6 | 4 | 4 | 8 |
| Completed | 3 | 5 | 6 | 4 | 4 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Hemihydrate/Maleate/Maleate Gel | Maleate/Maleate Gel/Hemihydrate | Maleate Gel/Hemihydrate/Maleate | Hemihydrate/Maleate Gel/Maleate | Maleate/Hemihydrate/Maleate Gel | Maleate Gel/Maleate/Hemihydrate |
|---|---|---|---|---|---|---|
| Started | 3 | 5 | 6 | 4 | 4 | 8 |
| Completed | 3 | 5 | 6 | 4 | 4 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Hemihydrate/Maleate/Maleate Gel | Maleate/Maleate Gel/Hemihydrate | Maleate Gel/Hemihydrate/Maleate | Hemihydrate/Maleate Gel/Maleate | Maleate/Hemihydrate/Maleate Gel | Maleate Gel/Maleate/Hemihydrate |
|---|---|---|---|---|---|---|
| Started | 3 | 5 | 6 | 4 | 4 | 8 |
| Completed | 3 | 5 | 6 | 4 | 4 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Assessed from subject response to survey question asking about tolerability of medicine upon instillation, using a 0 through 7 scale, with 0=complete comfort and 7=worst pain imaginable.
| Units on a scale | Timolol Hemihydrate 0.5% | Timolol Maleate 0.5% | Timolol Maleate Gel Forming Solution 0.5% |
|---|---|---|---|
| Stinging on Instillation | 0.6 ± 1.0 | 1.0 ± 1.4 | 0.6 ± 1.0 |
Assessed by investigator using a slit lamp and a photographic grading scale. Photographs were graded: grade 0, grade 1, grade 2, grade 3. The higher the graded the worse the hyperemia.
| Units on a scale | Timolol Hemihydrate 0.5% | Timolol Maleate 0.5% | Timolol Maleate Gel Forming Solution 0.5% |
|---|---|---|---|
| Conjunctival Hyperemia | 0.2 ± 0.5 | 0.4 ± 0.5 | 0.3 ± 0.5 |
| Seconds | Timolol Hemihydrate 0.5% | Timolol Maleate 0.5% | Timolol Maleate Gel Forming Solution 0.5% |
|---|---|---|---|
| Tear Film Break-up Time | 8.5 ± 6.1 | 7.7 ± 4.9 | 8.5 ± 5.7 |
Assessed by the investigator using a slit lamp and Oxford Scheme, grading 0,1,2,3,4,5. The higher the grade the worse the staining.
| Units on a scale | Timolol Hemihydrate 0.5% | Timolol Maleate 0.5% | Timolol Maleate Gel Forming Solution 0.5% |
|---|---|---|---|
| Corneal Staining Grade | 1.2 ± 0.9 | 1.1 ± 0.9 | 1.0 ± 0.8 |
Assessed by the investigator using a slit lamp, counting the number of spots.
| Number of spots | Timolol Hemihydrate 0.5% | Timolol Maleate 0.5% | Timolol Maleate Gel Forming Solution 0.5% |
|---|---|---|---|
| Corneal Staining Count | 10.5 ± 12.5 | 10.4 ± 13.4 | 8.3 ± 8.3 |
| mm of mercury | Timolol Hemihydrate 0.5% | Timolol Maleate 0.5% | Timolol Maleate Gel Forming Solution 0.5% |
|---|---|---|---|
| Intraoclular Pressure | 16.3 ± 3.1 | 16.2 ± 2.4 | 16.2 ± 2.2 |
Schirmer's measures basic tear function. The higher the number, the less dry the eye.
| mm of moisture | Timolol Hemihydrate 0.5% | Timolol Maleate 0.5% | Timolol Maleate Gel Forming Solution 0.5% |
|---|---|---|---|
| Basic Schirmer's | 17.7 ± 9.7 | 14.8 ± 7.3 | 15.4 ± 6.4 |
Assessed by investigator using a slit lamp and the Oxford Scheme, grading 0,1,2,3,4,5 according to pictures provided. The higher the grade the worse the staining.
| Units on a scale | Timolol Hemihydrate 0.5% | Timolol Maleate 0.5% | Timolol Maleate Gel Forming Solution 0.5% |
|---|---|---|---|
| Conjunctival Staining - Nasal Grade | 1.2 ± 0.9 | 1.1 ± 1.0 | 1.3 ± 1.0 |
Assessed by investigator using slit lamp and counting number of spots.
| number of spots | Timolol Hemihydrate 0.5% | Timolol Maleate 0.5% | Timolol Maleate Gel Forming Solution 0.5% |
|---|---|---|---|
| Conjunctival Staining - Nasal Count | 11.0 ± 12.5 | 10.3 ± 15.7 | 12.9 ± 14.8 |
Assessed by investigator using a slit lamp and Oxford Scheme, grading 0,1,2,3,4,5 according to pictures provided. The higher the grade the worse the staining.
| Units on a scale | Timolol Hemihydrate 0.5% | Timolol Maleate 0.5% | Timolol Maleate Gel Forming Solution 0.5% |
|---|---|---|---|
| Conjunctival Staining - Temporal Grade | 0.8 ± 0.6 | 0.7 ± 0.7 | 0.8 ± 0.7 |
Assessed by investigator using a slit lamp and counting number of spots.
| number of spots | Timolol Hemihydrate 0.5% | Timolol Maleate 0.5% | Timolol Maleate Gel Forming Solution 0.5% |
|---|---|---|---|
| Conjunctival Staining - Temporal Count | 4.7 ± 7.3 | 4.8 ± 8.6 | 5.3 ± 6.7 |
The visual acuity score is a count of the number of letters the subject successfully read from the eye chart. The higher the score, the better the vision.
| number of letters | Timolol Hemihydrate 0.5% | Timolol Maleate 0.5% | Timolol Maleate Gel Forming Solution 0.5% |
|---|---|---|---|
| Visual Acuity | 52.3 ± 5.6 | 52.5 ± 6.1 | 51.4 ± 5.8 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Timolol Hemihydrate 0.5% | — | 0/30 (0%) | 2/30 (6.7%) |
| Timolol Maleate 0.5% | — | 0/30 (0%) | 2/30 (6.7%) |
| Timolol Maleate Gel Forming Solution 0.5% | — | 0/30 (0%) | 0/30 (0%) |
| Event | Timolol Hemihydrate 0.5% | Timolol Maleate 0.5% | Timolol Maleate Gel Forming Solution 0.5% |
|---|---|---|---|
| TearingEye disorders | 2/30 | 0/30 | 0/30 |
| Blurred VisionEye disorders | 0/30 | 2/30 | 0/30 |
| Age, Continuous(years) | Overall |
|---|---|
| Mean | 66.3 ± 8.9 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 15 |
| Male | 15 |
| Region of Enrollment(participants) | Overall |
|---|---|
| United States | 30 |
The record gives a start of Nov 2008, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2010, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Timolol
Vistakon Pharmaceuticals